drugset / Trial / NCT05747313
Chidamide in Combination With Vincristine Metronomic Chemotherapy for Advanced Triple-negative Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
The mechanism of action of cidabenamide and the advantages of vincristine metronomic chemotherapy make it possible to combine the two drugs. Therefore, it is necessary to conduct a prospective study to investigate the value of chidamide in combination with vincristine metronomic treatment for triple-negative breast cancer.
Timeline
- Start
- 2022-11-01
- Primary completion
- 2023-06-01
- Completion
- 2023-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tucidinostat | Small molecule | — | Oral |
| Background | Vincristine | Small molecule | 40 mg | Oral |